CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 17 enrolled
Drug / intervention
Testim, 1% testosterone geldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00645658
NCT00645658N/ACompleted
CompareCT.gov

Testosterone Replacement Therapy in Advanced Chronic Kidney Disease

Palo Alto Veterans Institute for Research·interventional·Posted Mar 28, 2008·Updated Aug 26, 2024

In Brief

A clinical study evaluating Testim, 1% testosterone gel for Kidney Failure and Kidney Diseases. Completed, enrolled 17 participants across 2 sites.

Detailed Summary

Muscle wasting is common in advanced chronic kidney disease (CKD) and adversely affects morbidity and mortality. In 2/3 of males with advanced CKD serum testosterone (TT) levels are reduced, and likely contributes to the wasting. As TT in relatively safe physiologic replacement doses, increases muscle mass in otherwise normal TT deficient subjects, we hypothesize that physiologic TT replacement will be effective in preventing and treating the loss of muscle mass and function in CKD patients, will improve quality of life and may reduce some cardiovascular disease (CVD) risk factors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Failure, Kidney Diseases
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 28, 2008
Enrollment StartAug 1, 2007
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.3 years ago

Interventions

Testim, 1% testosterone geldrug

Subjects apply contents of gel packet (Testim, 1% testosterone gel) to skin daily.